Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Alzheimer's Disease Diagnostics and Therapeutics Market Size and Share Analysis 2023-2028
The Alzheimer’s Disease Diagnostics and Therapeutics Market is projected to experience substantial growth during the forecast period (2023-2028), increasing from USD 7,277 million in 2023 to USD 9,314 million by 2028, at a Compound Annual Growth Rate (CAGR) of 5.06%.
Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that affects the brain’s nerve cells or neurons, leading to memory loss, impaired thinking and language skills, and behavioral changes. The prevalence of Alzheimer’s disease is rapidly increasing, but unfortunately, only approximately one in four individuals with the condition receive a formal diagnosis.
|No. of Pages||
USD 6.9 billion in 2021
Product and Geography
|No. of Companies Mentioned||
The emergence of the COVID-19 pandemic had a significant impact on the Alzheimer’s disease diagnostics and therapeutics market. Global diagnostic and therapeutic procedures for Alzheimer’s were affected as hospital and diagnostic center visits declined due to government regulations imposed worldwide in early 2020. Studies have indicated that patients with dementia faced an elevated risk of severe disease and death when infected with COVID-19, resulting in reduced treatment and diagnostic visits to healthcare facilities. However, with improved access to Alzheimer’s diagnostic and therapeutic services compared to the initial stages of the pandemic, the market is expected to regain its growth momentum during the studied period.
Key drivers contributing to the growth of the Alzheimer’s disease diagnostics and therapeutics market include the increased utilization of biomarkers in Alzheimer’s diagnosis and drug development and the escalating prevalence of the disease globally. According to a report by the World Health Organization (WHO) in September 2022, approximately 55 million people worldwide are living with dementia, with nearly 10 million new cases reported annually. Alzheimer’s disease constitutes the most common form of dementia, accounting for about 60-70% of all dementia cases.
Moreover, both government and non-government entities are making substantial investments in the development of diagnostics and therapeutics for Alzheimer’s disease in response to its growing prevalence. Initiatives like the ADDF Diagnostics Accelerator, which launched new research investments in June 2021 to develop digital biomarkers for Alzheimer’s diagnosis, further bolster the market’s growth.
The advancement of diagnostic technologies and ongoing research activities in the field are encouraging companies to enhance their product offerings and introduce new ones. Additionally, strategic initiatives like mergers, acquisitions, collaborations, and investments into other companies are expected to complement the growth of the Alzheimer’s disease diagnostics and therapeutics market. For example, Brigham and Women’s Hospital in Boston, United States, commenced a clinical trial in November 2021 to test the safety and efficacy of a new nasal vaccine for Alzheimer’s disease, leading to the development of improved therapeutic options.
Despite the optimistic growth outlook, the market faces challenges in the form of high failure rates in clinical studies related to diagnosis and treatment, as well as difficulties in early diagnostics of Alzheimer’s, which may impede market growth during the forecast period. Nevertheless, with the use of biomarkers, increasing research and development efforts, and advanced diagnostic technologies, the studied market is expected to witness healthy growth in the coming years.
The market is segmented based on various factors, including product and geography.
Segmentation by Product
Therapeutics – Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Therapeutics
Diagnostics – Brain Imaging, CFS Test for Alzheimer’s Disease
Segmentation by Geography
North America – United States, Canada, Mexico
Europe – United Kingdom, Germany, France, Italy, Spain, and Rest of Europe
Asia-Pacific – China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific
Latin America – Brazil, Argentina, and Rest of Latin America
Middle East and Africa – GCC, South Africa, and Rest of Middle East and Africa
The studied market’s product segment is expected to witness the largest share in the therapeutics segment due to the rising prevalence of Alzheimer’s disease and a robust drug pipeline. Concurrently, the diagnostics segment is anticipated to have the largest end-user base owing to the increasing incidence of Alzheimer’s disease and the continued developments by key market players.
Within the market, North America is poised to hold the highest market share due to the escalating burden of Alzheimer’s disease and significant technological advancements in the region. Specifically, the United States is expected to command the highest market share, attributed to the country’s high disease burden, substantial healthcare expenditure, and the presence of key industry players.
Furthermore, North America is projected to experience substantial growth over the forecast period due to the increasing prevalence of Alzheimer’s disease among the aging population, substantial investments in research and development activities, and the introduction of new products in the region. For example, an interview with the Chief Science Officer of the Alzheimer’s Society of Canada in June 2021 highlighted that the number of people living with dementia in Canada is expected to surpass one million within the next decade, indicating a surge in demand for diagnostic and therapeutic products in the region.
Moreover, the growing aging population in the region contributes to the rising burden of Alzheimer’s disease, as older individuals are more susceptible to neurodegenerative conditions like Alzheimer’s, given its association with aging. The Alzheimer’s Association Report in March 2022 indicated that approximately 6.2 million individuals aged 65 years and above are currently living with Alzheimer’s-related dementia in the United States, with this number projected to reach 13.8 million by 2060.
The United States’ market is expected to flourish further due to the increasing number of research studies focused on the diagnosis and management of Alzheimer’s disease, alongside significant investments made by the government and private entities in Alzheimer’s research. An example is the initiation of a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 by the Salk Institute in October 2021, evaluating its safety in humans. Such promising pipeline drugs contribute to the development of more effective therapeutics for Alzheimer’s disease, thereby driving growth in the studied market in the United States.
The market for Alzheimer’s disease diagnostics and therapeutics is characterized by moderate competition and comprises several prominent players. Among these companies are F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc., Eisai Co. Ltd, Biogen Inc., Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc., Siemens Healthineers, Zydus Cadila, Merz Pharma, Teva Pharmaceutical Industries Ltd., and Adamas Pharmaceuticals Inc.
Key companies profiled in this report include F. Hoffmann-la Roche Ltd, Bristol-myers Squibb Company, Astrazeneca PLC., Corium Inc., Eisai Co. Ltd, Biogen, Johnson and Johnson, Eli Lilly and Company, Lupin, Abbvie Inc., Siemens Healthineers, Zydus Group (zydus Lifesciences Limited), Merz Pharma Gmbh & Co. KGAA, Teva PharmaceuticalsIndustries Ltd, Novartis AG.
Recent Industry Developments
In October 2022, Cyclo Therapeutics, Inc. announced the initiation of its Phase 2b study of Trappsol Cyclo for the treatment of Alzheimer’s disease, with a focus on reducing amyloid beta and tau. The Phase 2b study has received approval from the Institutional Review Board (IRB).
In September 2022, Esai Co., Ltd., and Biogen Inc. disclosed positive topline findings from Eisai’s extensive global Phase 3 confirmatory Clarity AD clinical trial of lecanemab. Lecanemab is an investigational anti-amyloid beta (Aβ) protofibril antibody aimed at treating mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease.
Key Questions Answered
What is the study period of the Alzheimer’s Disease Diagnostics and Therapeutics Market?
The study period of the Alzheimer’s Disease Diagnostics and Therapeutics Market spans from 2019 to 2027.
What is the growth rate of the Alzheimer’s Disease Diagnostics and Therapeutics Market?
The Alzheimer’s Disease Diagnostics and Therapeutics Market is experiencing a Compound Annual Growth Rate (CAGR) of 5.06% over the next five years.
What is the size of the Alzheimer’s Disease Diagnostics and Therapeutics Market?
The Alzheimer’s Disease Diagnostics and Therapeutics Market is anticipated to achieve a value of USD 7,277 million in 2023 and is projected to grow at a CAGR of 5.06%, reaching USD 9,314 million by 2028.
Which region exhibits the highest growth rate in the Alzheimer’s Disease Diagnostics and Therapeutics Market?
The Asia Pacific region demonstrates the highest Compound Annual Growth Rate (CAGR) over the period of 2019 to 2027.
Which region holds the largest share in the Alzheimer’s Disease Diagnostics and Therapeutics Market?
As of 2021, North America commands the highest market share in the Alzheimer’s Disease Diagnostics and Therapeutics Market.
Who are the key players in the Alzheimer’s Disease Diagnostics and Therapeutics Market?
The major companies operating in the Alzheimer’s Disease Diagnostics and Therapeutics Market include F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Johnson & Johnson, and Eli Lilly and Company.